A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Part of paid clinical trials in Duarte, California.

Sponsor
Allotera Therapeutics
Study ID
NCT06514794
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lymphoblastic Lymphoma
  • T-cell Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex
ALL
Age
1 Year - N/A
Healthy Volunteers
Not accepted

Interventions

  • WU-CART-007 — BIOLOGICAL
    A single IV infusion of WU-CART-007

Study Details

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response

Key Dates

First listed
Jul 23, 2024
Start date
Jan 31, 2025
Status verified
Aug 2026
Primary completion
Dec 30, 2026
Completion
Dec 30, 2028

Study Design

Enrollment
125 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: WU-CART-007
    A CD7-directed chimeric antigen receptor (CAR) T-cell product. Lymphodepletion

Primary Outcome Measure

R/R Cohort - Composite Complete Response Rate [ Time Frame: 24 months ]

Central Contacts

Locations (15)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Ibrahim Aldoss, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital Los AngelesLos AngelesCalifornia90027
Amneh Aljazzar
[email protected]
323-361-4156
Amber Medina
[email protected]
(323) 361-5654
Deepa Bhojwani, MD (PRINCIPAL_INVESTIGATOR)
Colorado Blood Cancer InstituteDenverColorado80218
Alireza Eghtedar, M.D. (PRINCIPAL_INVESTIGATOR)
Children's National HospitalWashington D.C.District of Columbia20010
Mallika Khanna
[email protected]
202-476-8938
Keri Toner, MD (PRINCIPAL_INVESTIGATOR)
H. Lee Moffitt Cancer Center and Research Institute HospitalTampaFlorida33612
Garrett Welch
[email protected]
Rawan Faramand, M.D. (PRINCIPAL_INVESTIGATOR)
Children's Hospital of AtlantaAtlantaGeorgia30329
Judson Russell
[email protected]
404-433-6653
Muna Qayed, MD (PRINCIPAL_INVESTIGATOR)
Washington University Saint LouisSt LouisMissouri63108
Katie Stricker
[email protected]
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
Jeremy Rubinstein, MD
[email protected]
Oncology Hematology CareCincinnatiOhio45226
Doug Hart
[email protected]
513-751-2273
Ahmed Galal, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19390
Brooke Leibfreid
[email protected]
TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular TherapyNashvilleTennessee37203
Stephen Strickland, M.D. (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030
Elias Jabbour, M.D. (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Transplant and Cellular Therapy Methodist HospitalSan AntonioTexas78229
Christian Herrera
[email protected]
210-575-6026
Nosha Farhadfar, M.D. (PRINCIPAL_INVESTIGATOR)
Sarah Cannon, Virginia Oncology AssociatesNorfolkVirginia23502
Wendi Gobhardt
[email protected]
757-213-5813
Gary L. Simmons, D.O. (PRINCIPAL_INVESTIGATOR)
Seattle Children's HospitalSeattleWashington98105
Adam Lamble, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By research site
City of Hope· Duarte, CAChildren's Hospital Los Angeles· Los Angeles, CAColorado Blood Cancer Institute· Denver, COChildren's National Hospital· Washington D.C., DCH. Lee Moffitt Cancer Center and Research Institute Hospital· Tampa, FLChildren's Hospital of Atlanta· Atlanta, GA

Related Studies